Nephros, Inc. — 2016 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2016; filed March 20, 2017. This is an annual report, not a standalone fourth-quarter report. Nephros develops and sells water ultrafiltration products and hemodiafiltration (HDF) systems for dialysis treatment.
Financial results and liquidity
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | $2.320 million | $1.944 million |
| Gross profit / gross margin | $1.294 million / 55.8% | $1.060 million / 54.5% |
| Operating expenses | $4.163 million | $4.481 million |
| Operating loss | $2.869 million | $3.421 million |
| Net loss | $3.032 million | $3.088 million |
| Cash used in operating activities | $2.112 million | $3.815 million |
| Cash at year-end | $275,000 | $1.248 million |
| Working capital | $369,000 | $1.505 million |
Revenue increased 19%, principally from higher filter sales. Product revenue was $2.093 million; license, royalty and other revenue was $227,000. SG&A fell 17% to $2.854 million, partly offset by a 31% increase in R&D to $1.079 million. The company reported $172,000 of interest expense, including $77,000 of interest on notes and $53,000 of debt-discount amortization. The 2015 net result included a $2.099 million warrant fair-value gain and $1.761 million warrant modification expense; these unusual items complicate year-over-year comparisons.
At year-end, total assets were $2.678 million, total liabilities $2.011 million and stockholders’ equity $667,000. The balance sheet carried an unsecured note at $838,000 net of debt discount and issuance costs; the notes bear 11% interest and principal is due June 7, 2019. Cash decreased by $973,000 during 2016. Financing provided $1.188 million, principally from the note issuance. No off-balance-sheet arrangements were reported.
Changes, business developments and outlook
- Hospital and dialysis ultrafilter sales supported growth. Nephros began shipping its S100 hospital point-of-use filter in Q3 2016 and reached full production by year-end. It received FDA 510(k) clearance for HydraGuard 10-inch in December 2016.
- HDF evaluation at the Renal Research Institute concluded in June 2016 after more than 1,200 treatments had been performed by June. DaVita’s evaluation was not expected to restart in the near term; Vanderbilt began treating patients in early 2017. The company was developing HDF System version 2.0 to support scale manufacturing and potentially lower treatment costs.
- Management expected to begin shipping HydraGuard in Q2 2017, with full production in Q3; a flushable version was also expected in Q3. These are expectations, not guarantees. EndoPur received FDA clearance in March 2017, after year-end, with shipments expected in Q2 2017.
- Management said existing cash, anticipated new-product sales and approximately $1.2 million from a March 2017 private placement were expected to fund operations at least into 2018, depending on product launch timing and market acceptance. The placement was expected to close on or about March 22, 2017, subject to customary conditions; it included 4,059,994 shares and warrants for an equal number of shares at $0.30.
Risks, contingencies and unusual items
- Going concern: The auditor’s report and management disclosure state that recurring losses and operating cash outflows raise substantial doubt about the company’s ability to continue as a going concern. The financial statements include no adjustments for the outcome of this uncertainty. Nephros reported an accumulated deficit of $120.285 million and had never generated positive operating cash flow in the years presented.
- Funding and dilution: Management said additional financing would be needed; failure to raise capital could force the company to curtail operations or cease business. The 2017 placement included warrants, while the 2016 notes also carry warrants. Lambda beneficially owned approximately 61% of common stock as of March 17, 2017.
- Commercial and execution risks: Product acceptance, pricing, reimbursement, manufacturing scale-up, third-party suppliers and distributors, and the ability to expand sales remain uncertain. Four customers accounted for 55% of 2016 revenue and 59% of year-end receivables.
- Regulatory: A May 2015 FDA warning letter cited quality-system and medical-device-reporting deficiencies. The company reported corrective actions, no observations at the February 2016 inspection, and an April 2016 FDA letter indicating the cited deficiencies appeared addressed. Regulatory compliance and future clearances remain risks.
- Commitments: Medica purchase commitments were approximately €1.2 million for 2016; minimum purchase levels for 2017–2022 were to be mutually agreed, and the 2017 level had not been formalized. Reported lease and employment obligations totaled approximately $790,000, including $356,000 due within one year.
- The company reported no pending legal proceedings. Management stated that disclosure controls and internal control over financial reporting were effective at December 31, 2016. A prior material weakness relating to warrant accounting had been remediated.
Key facts investors should verify
- Whether the March 2017 financing closed as planned, the net proceeds after placement fees, and the resulting share and warrant dilution.
- Actual cash burn, cash runway and financing requirements compared with management’s expectation of funding into 2018.
- Subsequent revenue growth, gross margins, customer concentration and market uptake of new filtration products.
- HDF commercialization progress, including clinical and economic evidence, customer adoption, and version 2.0 manufacturing and cost targets.
- Note terms and related-party holdings, including the 11% rate, June 2019 maturity and warrant obligations; also confirm Medica’s 2017 purchase commitment.